Daily Sepsis Research Analysis
Analyzed 53 papers and selected 3 impactful papers.
Summary
Two prospective studies advance early risk stratification in sepsis: alactic base excess (ABE) independently predicts sepsis-associated acute kidney injury, and a composite of HDL2b plus SOFA improves 28-day mortality prediction. A systematic review maps sequencing technologies for rapid antimicrobial resistance detection in bloodstream infections, proposing context-specific diagnostic strategies to guide therapy.
Research Themes
- Early prognostic biomarkers in sepsis
- Risk stratification integrating organ failure and lipid subclasses
- Rapid genomic diagnostics for antimicrobial resistance in bloodstream infections
Selected Articles
1. High-density lipoprotein 2b combined with sequential organ failure assessment score as a novel prognostic indicator for sepsis patients: a prospective study.
In a three-ICU prospective cohort, plasma HDL2b was lower in sepsis than controls and lower in non-survivors versus survivors. A composite HDL2b+SOFA score outperformed either metric alone for predicting 28-day and in-hospital mortality (AUC 0.806 vs. 0.782 for SOFA). Multivariable analysis supported HDL2b+SOFA as an independent predictor.
Impact: Combining an accessible lipid subfraction with SOFA yields measurably better mortality risk stratification, enabling earlier identification of high-risk sepsis patients.
Clinical Implications: HDL2b+SOFA could refine triage and escalation decisions (e.g., monitoring intensity, therapy prioritization). Implementation requires assay availability and workflow integration.
Key Findings
- Sepsis patients had significantly lower HDL2b levels than non-septic controls (p<0.001).
- Non-survivors showed lower HDL2b than survivors; higher HDL2b+SOFA scores correlated with higher 28-day and in-hospital mortality.
- AUCs for 28-day mortality: HDL2b 0.755, SOFA 0.782, HDL2b+SOFA 0.806; HDL2b+SOFA was an independent predictor in multivariable analysis (OR 1.321, 95% CI 1.028–1.698).
Methodological Strengths
- Prospective, multi-ICU enrollment with standardized day-1 SOFA scoring
- Objective HDL2b quantification via microfluidic chip and ROC-based performance comparison
Limitations
- Single-country, three-ICU cohort without reported external validation
- Biomarker access (HDL2b assay) may limit generalizability and adoption
Future Directions: External multicenter validation and impact analyses testing whether HDL2b+SOFA-guided care improves outcomes are warranted.
BACKGROUND: Sepsis is a state of life-threatening organ dysfunction caused by a dysregulated host response to infection, leading to consecutive organ failure and lethal outcome. The purpose of this study is to assess the value of the combined use of plasma high-density lipoprotein 2b (HDL2b) level and Sequential Organ Failure Assessment (SOFA) score in predicting short-term mortality from sepsis. MATERIALS AND METHODS: A prospective, observational study was conducted in patients with sepsis and non-septic controls admitted to three intensive care units (ICUs) from January 2020 to December 2021. SOFA scores were recorded on the first day after admission. Blood samples were collected from each enrolled patient and the levels of HDL2b were analyzed using microfluidic chip technology. Receiver-operator characteristic curve (ROC) analyses were conducted to determine the values of plasma HDL2b level, SOFA score and the combined HDL2b levels and SOFA score (HDL2b + SOFA) in predicting the prognosis of mortality, respectively. The primary endpoint was 28-day mortality and the secondary outcome was total in-hospital mortality.
2. Alactic base excess as an early predictor of sepsis-associated acute kidney injury: a prospective observational study.
In 369 adults with sepsis, baseline ABE independently predicted SA‑AKI: each 1 mmol/L less negative ABE was associated with an 11% reduced AKI risk (adjusted OR 0.89). More negative ABE correlated with both higher AKI incidence and in-hospital mortality, whereas 12- and 24-hour ABE were not independently predictive.
Impact: ABE repurposes a routine acid–base parameter into an actionable early kidney risk biomarker, particularly valuable where advanced assays are limited.
Clinical Implications: ABE at admission can enhance early SA‑AKI risk stratification to trigger nephroprotective strategies and monitoring, especially in resource-limited ICUs.
Key Findings
- AKI occurred in 43% (159/369) of sepsis patients; 17.9% required RRT.
- Baseline ABE independently predicted AKI (adjusted OR 0.89 per 1 mmol/L increase; 95% CI 0.80–0.99; p=0.030).
- More negative baseline ABE associated with higher AKI incidence and in-hospital mortality; ABE at 12 and 24 h was not independently predictive.
Methodological Strengths
- Prospective design with predefined timepoints (0, 12, 24 h) and KDIGO-defined AKI
- Clinical trial registration (CTRI/2022/07/044168) and multivariable modeling
Limitations
- Single-center cohort from a tertiary hospital limits generalizability
- No external validation; only in-hospital outcomes were assessed
Future Directions: Validate ABE thresholds across diverse settings and test ABE-guided AKI prevention bundles in pragmatic trials.
BACKGROUND: Sepsis-associated acute kidney injury (SA-AKI) is a major contributor to morbidity and mortality in critically ill patients. Early detection and intervention are essential for improving clinical outcomes. This study investigates the predictive utility of alactic base excess (ABE) as an early biomarker for SA-AKI within the first 24 h of hospital or emergency department admission. METHODS: A prospective observational study was conducted in a tertiary care hospital in Eastern India from May 2022 to April 2023. Adult patients (≥ 18 years) diagnosed with sepsis at hospital/emergency/intensive care unit (ICU) admission were enrolled. ABE was calculated at 0, 12, and 24 h after admission to hospital or emergency department by adjusting standard base excess for serum lactate levels. The primary outcome was the development of acute kidney injury (AKI), defined by Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Secondary outcomes included AKI severity, stratification by ABE ranges, and in-hospital mortality. RESULTS: Among 369 enrolled patients, 159 (43%) developed AKI, and 66 (17.9%) required renal replacement therapy (RRT). Baseline ABE remained a significant independent predictor, with each 1 mmol/L increase (less negative value) associated with an 11% reduction in AKI risk (adjusted OR 0.89, 95% CI 0.80-0.99, p = 0.030). More negative baseline ABE values were significantly associated with both increased AKI incidence and mortality. ABE measurements at 12 and 24 h were not independently predictive. CONCLUSIONS: Baseline ABE is a cost-effective, easily obtainable biomarker that independently associates with SA-AKI and correlates with in-hospital mortality. Its early use in sepsis management may improve risk stratification and outcomes, especially in resource-limited settings. Multicenter validation is recommended. Trial registration number The study was registered with the Clinical Trial Registry of India (CTRI/2022/07/044168), dated 20/07/2022.
3. Comparative Evaluation of Sequencing Technologies for Detecting Antimicrobial Resistance in Bloodstream Infections.
This systematic review compares WGS, targeted NGS, mNGS, and long-read platforms for AMR detection in BSIs, detailing trade-offs in sensitivity, turnaround time, and cost. It recommends context-specific pathways—rapid targeted sequencing for common resistance with broader metagenomics for complex or culture-negative cases—to complement conventional diagnostics.
Impact: Provides an actionable framework to integrate sequencing into sepsis workflows, potentially shortening time-to-effective therapy and improving outcomes in culture-negative BSIs.
Clinical Implications: Adopt tiered diagnostics: deploy rapid tNGS for common AMR within 8–24 h and escalate to mNGS for polymicrobial or culture-negative cases, while building pipelines for clinical interpretation.
Key Findings
- Targeted NGS can detect known resistance determinants within 8–24 hours, expediting therapy decisions.
- WGS provides comprehensive resistance profiling (24–48 hours), while mNGS broadens detection to rare/unexpected pathogens at higher cost/turnaround.
- Sequencing complements culture, improving diagnostic yield especially in culture-negative or polymicrobial BSIs.
Methodological Strengths
- Systematic comparative framework across multiple sequencing modalities
- Quantitative appraisal of sensitivity, turnaround time, and cost to guide clinical adoption
Limitations
- Heterogeneous study designs and lack of unified outcome metrics limit meta-analytic synthesis
- Clinical utility depends on local infrastructure, bioinformatics capacity, and stewardship integration
Future Directions: Prospective evaluations integrating sequencing into sepsis pathways should measure time-to-effective therapy, mortality, and cost-effectiveness.
Bloodstream infections (BSIs) pose a significant global health challenge, particularly due to the increasing prevalence of antimicrobial resistance (AMR). Timely and accurate identification of pathogens and resistance determinants is critical for guiding appropriate therapy and improving patient outcomes. Traditional culture-based diagnostics are limited by prolonged turnaround times and reduced sensitivity, especially in culture-negative or polymicrobial infections. This review systematically examined current and emerging sequencing technologies for AMR detection in BSIs, including whole-genome sequencing (WGS), targeted next-generation sequencing (tNGS), metagenomic next-generation sequencing (mNGS), and long-read sequencing platforms (Oxford Nanopore, PacBio). We compared their clinical performance using key metrics such as diagnostic sensitivity, turnaround time, and cost, highlighting contexts in which each technology is most effective. For example, tNGS can achieve the rapid detection of known resistance genes within 8-24 h, while WGS provides comprehensive genome-wide resistance profiling over 24-48 h. mNGS offers broader detection, including rare or unexpected pathogens, although at higher cost and longer processing times. Our analysis identifies specific strengths and limitations of each approach, supporting the use of context-specific strategies, such as combining rapid targeted sequencing for common pathogens with broader metagenomic approaches for complex cases, to improve diagnostic yield and guide antimicrobial therapy. Quantitative comparisons indicate that sequencing technologies can complement conventional methods, particularly in cases where culture-based approaches fail. In conclusion, sequencing-based diagnostics offer measurable improvements in sensitivity and speed over traditional methods for AMR detection in BSIs. Future work should focus on optimizing workflows, integrating sequencing data into clinical decision-making, and validating approaches in prospective studies.